Search

Displaying results 4011 - 4020 of 4860 in total
  1. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira.

  2. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.

  3. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.

  4. Drug

    Ala-geninthiocin

    go.drugbank.com/drugs/DB15657
    Experimental

    [A192840] It has exhibited potent _in vitro_ activity against gram-positive bacteria including _Staphylococcus aureus_, _Bacillus subtilis_, _Mycobacterium smegmatis_, and _Micrococcus luteus_.

  5. Drug

    Nanoparticle Epirubicin

    go.drugbank.com/drugs/DB16248
    Investigational

    It is a novel [epirubicin] drug-conjugated polymeric micelle.

  6. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    It is thought to have widespread effects on the immune system, and effective in treating infections and immunological issues.

  7. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically active.

  8. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    It is an attractive target for immunotherapy.

  9. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003

  10. Drug

    Sovleplenib

    go.drugbank.com/drugs/DB17557
    Investigational

    It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).